MX2024007301A - Peptidos y metodos para usar en el tratamiento del dolor. - Google Patents

Peptidos y metodos para usar en el tratamiento del dolor.

Info

Publication number
MX2024007301A
MX2024007301A MX2024007301A MX2024007301A MX2024007301A MX 2024007301 A MX2024007301 A MX 2024007301A MX 2024007301 A MX2024007301 A MX 2024007301A MX 2024007301 A MX2024007301 A MX 2024007301A MX 2024007301 A MX2024007301 A MX 2024007301A
Authority
MX
Mexico
Prior art keywords
peptides
methods
pain treatment
kits
modulating
Prior art date
Application number
MX2024007301A
Other languages
English (en)
Spanish (es)
Inventor
Stéphane Gaillard
Francis Castets
Abdelaziz Moqrich
Original Assignee
Tafalgie Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tafalgie Therapeutics filed Critical Tafalgie Therapeutics
Publication of MX2024007301A publication Critical patent/MX2024007301A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024007301A 2021-12-17 2022-12-19 Peptidos y metodos para usar en el tratamiento del dolor. MX2024007301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21306835 2021-12-17
PCT/EP2022/086559 WO2023111348A1 (en) 2021-12-17 2022-12-19 Peptides and methods for use in treating pain

Publications (1)

Publication Number Publication Date
MX2024007301A true MX2024007301A (es) 2024-06-26

Family

ID=79317102

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007301A MX2024007301A (es) 2021-12-17 2022-12-19 Peptidos y metodos para usar en el tratamiento del dolor.

Country Status (12)

Country Link
US (1) US20250051395A1 (cg-RX-API-DMAC7.html)
EP (1) EP4447991A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024547029A (cg-RX-API-DMAC7.html)
KR (1) KR20240126864A (cg-RX-API-DMAC7.html)
CN (1) CN118401249A (cg-RX-API-DMAC7.html)
AR (1) AR129864A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022413983A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239578A1 (cg-RX-API-DMAC7.html)
IL (1) IL313183A (cg-RX-API-DMAC7.html)
MX (1) MX2024007301A (cg-RX-API-DMAC7.html)
TW (1) TW202344689A (cg-RX-API-DMAC7.html)
WO (1) WO2023111348A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026119985A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating wounds and inflammatory diseases
WO2026119983A1 (en) * 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
EP2801369A1 (en) 2013-05-06 2014-11-12 Centre National De La Recherche Scientifique TAFA4 compounds and uses thereof for treating pain
CN108699604A (zh) 2016-03-08 2018-10-23 艾克斯-马赛大学 用于预测急性疼痛转变为慢性疼痛的myo1a以及myo1a用于治疗疼痛的用途

Also Published As

Publication number Publication date
TW202344689A (zh) 2023-11-16
JP2024547029A (ja) 2024-12-26
AU2022413983A1 (en) 2024-06-13
KR20240126864A (ko) 2024-08-21
CA3239578A1 (en) 2023-06-22
CN118401249A (zh) 2024-07-26
AR129864A1 (es) 2024-10-09
US20250051395A1 (en) 2025-02-13
EP4447991A1 (en) 2024-10-23
WO2023111348A1 (en) 2023-06-22
IL313183A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
PH12020551427A1 (en) Epinephrine spray formulations
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
CL2019002220A1 (es) Gasotransmisor electroquímico que genera composiciones y métodos de uso de los mismos y apósitos y sistemas de tratamiento que incorpora los mismos.
MX2021007948A (es) Inhibidores de proteina de activacion de fibroblastos.
MX2022001933A (es) Inhibidores de enzimas.
MX2022009435A (es) Composiciones y metodos para el tratamiento de enfermedades oculares.
MX2024002989A (es) Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il )-benzonitrilo.
CO2022000481A2 (es) Inhibidores de enzimas
CL2023002549A1 (es) Ciertos compuestos de pladienolida y métodos de uso (divisional).
CL2023003259A1 (es) Composiciones y métodos para el tratamiento de la depresión.
BR112022015768A2 (pt) Métodos de tratamento e prevenção de arritmias de enxerto
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
MX2024014419A (es) Peptidos y metodos para usar en el tratamiento del dolor
JOP20220259A1 (ar) تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها
EA202193111A1 (ru) Композиции и способы для лечения рака
AR128163A1 (es) Ácido láctico y análogos del mismo para uso en regular y/o promover el aumento de tejidos
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
CL2025000127A1 (es) Uso de aficamten para tratar la miocardiopatía hipertrófica no obstructiva.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
CO2022014199A2 (es) Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19
AR129864A1 (es) Péptidos y métodos para uso en tratar el dolor
MX2025014063A (es) Inhibidores de expresion y/o funcion
MX2024004416A (es) Nuevos moduladores de ehmt1 y ehmt2 y uso terapéutico de estos.
MX2025006287A (es) Trehalosa para el tratamiento de la enfermedad de huntington
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.